Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL +1.08%76 Cash-to-Debt is 0.07 as of Jun. 2026, which is at its 10-year median of 0.07. GuruFocus rates ASX:ACL with a GF Score™ of 76/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 9 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Australian Clinical Labs ranks worse than 88.89% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Australian Clinical Labs's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.07.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Australian Clinical Labscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Australian Clinical Labs's Cash-to-Debt or its related term are showing as below:
ASX:ACL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.12
Current: 0.07
During the past 7 years, Australian Clinical Labs's highest Cash to Debt Ratio was 0.12. The lowest was 0.04. And the median was 0.07.
ASX:ACL's Cash-to-Debt is ranked worse than 88.89% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs ASX:ACL: 0.07
Australian Clinical Labs (ASX:ACL) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Australian Clinical Labs Cash-to-Debt Related Terms
Australian Clinical Labs Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:ACL vs TMO, DHR, NTRA: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a Cash-to-Debt of 0.07 as of Jun. 2026. This is near median its historical median of 0.07. Over the past decade, Australian Clinical Labs' Cash-to-Debt has ranged from 0.04 to 0.12. According to the industry distribution chart, Australian Clinical Labs ranks #184 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 88.9%.
Is Australian Clinical Labs' Cash-to-Debt too high?
Australian Clinical Labs' current Cash-to-Debt of 0.07 is near median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.12. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. Australian Clinical Labs' value of 0.07 is 92.9% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #184 out of 207 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #184 out of 207 companies for Cash-to-Debt. This places Australian Clinical Labs in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Australian Clinical Labs' value of 0.07 is 92.9% below this benchmark. Historically, Australian Clinical Labs' own Cash-to-Debt has ranged from 0.04 to 0.12 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.98, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Cash-to-Debt of 0.07 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Cash-to-Debt is 0.07, which is near median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.80 — trading 5.1% below its estimated fair value. The current Cash-to-Debt is 0.07, which is near median its 10-year median of 0.07 and 92.9% below the Medical Diagnostics & Research industry median of 0.98. Australian Clinical Labs' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Cash-to-Debt is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.80 is trading 5.1% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
Cash-to-Debt: 0.07 (near median its 10-year median of 0.07)
GF Value™: A$2.95 vs. price of A$2.80 (5.1% below fair value)
Industry Position: 92.9% below the Medical Diagnostics & Research median (#184 of 207)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
76GF Score
Get the complete analysis for ASX:ACL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
